tumour necrosis factor inhibitor Latest Research Papers

Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study

Scandinavian Journal of Rheumatology ◽

10.1080/03009742.2021.1967046 ◽

2021 ◽

pp. 1-7

Author(s):

T Rusman ◽

MT Nurmohamed ◽

S Hoekstra ◽

CJ van Denderen ◽

RF van Vollenhoven ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Observational Study ◽

Disease Activity ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Inhibitor Treatment

Download Full-text

Tumour necrosis factor inhibitor monotherapy for CNS neurosarcoidosis

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp-2021-326267 ◽

2021 ◽

pp. jnnp-2021-326267

Author(s):

Jeffrey Marc Gelfand

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Paradoxical psoriasis caused by tumour necrosis factor inhibitor therapy

Clinical and Experimental Dermatology ◽

10.1111/ced.14500 ◽

2020 ◽

Author(s):

J. M. E. Boggs ◽

B. Ramsay ◽

M. Lynch

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Inhibitor Therapy ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Response to ‘Correspondence on ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’’ by Zheng et al

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-218907 ◽

2020 ◽

pp. annrheumdis-2020-218907

Author(s):

Dimitrios A Pappas ◽

Gregory St John ◽

Carol J Etzel ◽

Stefano Fiore ◽

Taylor Blachley ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Comparative Effectiveness ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Registry Study ◽

First Line ◽

Factor Inhibitor ◽

Synthetic Agents ◽

Necrosis Factor

Download Full-text

Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-218865 ◽

2020 ◽

pp. annrheumdis-2020-218865

Author(s):

Wenjie Zheng ◽

Pui-Ying Leong ◽

James Cheng-Chung Wei

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Comparative Effectiveness ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Registry Study ◽

First Line ◽

Factor Inhibitor ◽

Synthetic Agents ◽

Necrosis Factor

Download Full-text

Decision letter for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

10.1098/rsob.200099/v3/decision1 ◽

2020 ◽

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Inflammatory Diseases ◽

Tumour Necrosis Factor Inhibitor ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Tumour necrosis factor inhibitor-induced myositis in a patient with ulcerative colitis

Modern Rheumatology Case Reports ◽

10.1080/24725625.2020.1800958 ◽

2020 ◽

Vol 5 (1) ◽

pp. 156-161

Author(s):

Akitsu Yoshida ◽

Yasuhiro Katsumata ◽

Shinya Hirahara ◽

Masanori Hanaoka ◽

Moeko Ochiai ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Author response for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

10.1098/rsob.200099/v3/response1 ◽

2020 ◽

Author(s):

Juliane Totzke ◽

Scott A. Scarneo ◽

Kelly W. Yang ◽

Timothy A. J. Haystead

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Inflammatory Diseases ◽

Tumour Necrosis Factor Inhibitor ◽

Author Response ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Decision letter for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

10.1098/rsob.200099/v2/decision1 ◽

2020 ◽

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Inflammatory Diseases ◽

Tumour Necrosis Factor Inhibitor ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Review for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

10.1098/rsob.200099/v2/review2 ◽

2020 ◽

Author(s):

Sung Kim

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Inflammatory Diseases ◽

Tumour Necrosis Factor Inhibitor ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

tumour necrosis factor inhibitor
Recently Published Documents

TOTAL DOCUMENTS

H-INDEX

Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study

Tumour necrosis factor inhibitor monotherapy for CNS neurosarcoidosis

Paradoxical psoriasis caused by tumour necrosis factor inhibitor therapy

Response to ‘Correspondence on ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’’ by Zheng et al

Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’

Decision letter for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

Tumour necrosis factor inhibitor-induced myositis in a patient with ulcerative colitis

Author response for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

Decision letter for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

Review for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

Export Citation Format

tumour necrosis factor inhibitorRecently Published Documents

TOTAL DOCUMENTS

H-INDEX

Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study

Tumour necrosis factor inhibitor monotherapy for CNS neurosarcoidosis

Paradoxical psoriasis caused by tumour necrosis factor inhibitor therapy

Response to ‘Correspondence on ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’’ by Zheng et al

Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’

Decision letter for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

Tumour necrosis factor inhibitor-induced myositis in a patient with ulcerative colitis

Author response for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

Decision letter for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

Review for "TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases"

tumour necrosis factor inhibitor
Recently Published Documents